IN THIS ISSUE, The AnnaLs begins a series of articles critiquing the Agency for Health Care Policy and Research (AHCPR) Clinical Practice Guidelines. Perfetto and Mor-ris· provide a history of the development of the guidelines and the process that each guideline undergoes before being published. As these authors describe, the agency is under scrutiny by healthcare forces seeking to influence its work and congressional forces trying to determine whether the agency will continue to exist. Currently, few data exist describing the application of these guidelines to real-world healthcare systems and the guidelines' resulting impact on the quality and cost of care.
The development of any guideline in medicine is often controversial. The guidelines established under the auspices of the federal government can only help spark controversy. Arguments have ranged from the cry of cookbook medicine to hailing the guidelines as unbiased, costeffective help.2-4 Regardless of your position on these issues, the guidelines are likely to have enormous impact on the current managed care and group practice environment. Local discussion of the guidelines will follow the national debate as they are modified to allow sanction by group practices. Therefore, it is essential that these guidelines be thoroughly discussed and analyzed. To this end, clinicians experienced in these areas will critique the guidelines to begin a dialogue on how they should be used. Because several of these guidelines are already dated, relevant new data published since their release will be incorporated in the articles.
Critics of the AHCPR guidelines argue that a government program is not necessary to develop cost-effective guidelines. Groups such as the American College of Chest Physicians, the American Academy of Pediatrics, and the American Society of Health-System Pharmacists have developed position statements, protocols, and guidelines on the use of a number of therapeutic agents and disease management areas without the help of the government. Critical pathway development and disease management protocols are discussed daily in managed care organizations. Critics ask, "Why is it necessary to fund a government agency to produce what professional groups are already doing?" Republicans in Congress are asking these same questions and threatening to pull the plug on AHCPR funding altogether. s Supporters of AHCPR cite the unique way that the guidelines merge outcomes research with clinical guidelines, the unbiased nature of their work, the multidisciplinary expert panels assembled to prepare the guidelines, and that the guidelines are subjected to extensive peer review. Supporters argue that the modest investment in AHCPR will be paid back several-fold in healthcare savings when the guidelines are implemented.
Guidelines such as those produced by AHCPR present healthcare providers with a difficult dilemma. Lohr6 describes it more appropriately as a "tri-Iemma." How does one balance the sometimes differing needs of the individual patient, the system in which healthcare providers operate (i.e., the managed care system), and the broader society in which we live? Guidelines such as these will not end the debate on these issues; rather, it may fuel the fire of such debates. 7 ,8 Science and reasoning can take us only so far in resolving such issues. Ultimately, good patient care will continue to depend on the professionalism and ethical judgments of the clinician.
